Ink Scribd Numbing

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Ink Scribd Numbing
Generic name: LIDOCAINE HCL
Manufacturer: Prodigy Media Inc
Product type: HUMAN OTC DRUG
SPL set ID: 54173858-aff0-43b2-bc7b-c4ecab9bc3e5
SPL ID: 3f02b9de-fd8c-05db-e063-6294a90a7259
Version: 2
Effective date: 2025-09-17
Source export date: 2026-09-28
Source partition: 3
Source file: https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/fd09911bd1bc81f7f2faeb048e63855fe224e494376ae919a0035190e315c050/drug-label-0003-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:18:37

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application number		M017	openfda.application_number
brand name		Ink Scribd Numbing	openfda.brand_name
generic name		LIDOCAINE HCL	openfda.generic_name
manufacturer name		Prodigy Media Inc	openfda.manufacturer_name
ndc	package	70171-0029-1	openfda.package_ndc
ndc	product	70171-0029	openfda.product_ndc
ndc11	package	70171002901	derived:openfda.package_ndc
rxcui		1010895	openfda.rxcui
spl id		3f02b9de-fd8c-05db-e063-6294a90a7259	id
spl set id		54173858-aff0-43b2-bc7b-c4ecab9bc3e5	set_id
unii		V13007Z41A	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

Warnings For external use only. Avoid contact with eyes Stop use and ask a doctor if Condition worsens or symptoms persist for more than 7 days Symptoms clear up and occur again within a few days Do not use in large quantities, particularly over raw surfaces or blistered areas. Do not exceed the recommended daily dosage unless directed by a doctor. Do not use On wounds or damaged skin.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.